Home Casteddu.com	FAQ My Amedeo About	Flying Publisher
	The Medical Article of the Year 2008: Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661-78. Free full-text

HIV Infection

Free Subscription Articles published in Vaccine Retrieve available abstracts of 96 articles: HTML format

Single Articles

June 2008
1. CHESSON HW , Forhan SE, Gottlieb SL, Markowitz LE, et al
   The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination.
   Vaccine. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
2. KENNEDY JS , Co M, Green S, Longtine K, et al
   The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers.
   Vaccine. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
3. DAI K , Liu Y, Liu M, Xu J, et al
   Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes.
   Vaccine. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
4. ARRODE G , Hegde R, Jin Y, Singh DK, et al
   Nef modulates the immunogenicity of Gag encoded in a non-infectious HIV DNA vaccine.
   Vaccine. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
5. LEVIN MJ , Song LY, Fenton T, Nachman S, et al
   Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children.
   Vaccine. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
6. LIU J , Yu Q, Stone GW, Yue FY, et al
   CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8(+) T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals.
   Vaccine. 2008;.
   PubMed     Related articles    Abstract available
   
   
   May 2008
7. BART PA , Goodall R, Barber T, Harari A, et al
   EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium.
   Vaccine. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
8. ALLARD SD , Pletinckx K, Breckpot K, Heirman C, et al
   Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef.
   Vaccine. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
9. GIRARD MP , Bansal GP, Pedroza-Martins L, Dodet B, et al
   Mucosal immunity and HIV/AIDS vaccines Report of an International Workshop, 28-30 October 2007.
   Vaccine. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
10. MCCORMACK S , Stohr W, Barber T, Bart PA, et al
    EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    April 2008
11. FLORESE RH , Wiseman RW, Venzon D, Karl JA, et al
    Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: Influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
12. HINKULA J , Hagbom M, Wahren B, Schroder U, et al
    Safety and immunogenicity, after nasal application of HIV-1 DNA gagp37 plasmid vaccine in young mice.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
13. MEGATI S , Garcia-Hand D, Cappello S, Roopchand V, et al
    Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responses.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
14. BOBERG A , Gaunitz S, Brave A, Wahren B, et al
    Enhancement of epitope-specific cellular immune responses by immunization with HIV-1 peptides genetically conjugated to the B-subunit of recombinant cholera toxin.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
15. GUDMUNDSDOTTER L , Bernasconi D, Hejdeman B, Sandstrom E, et al
    Cross-clade immune responses to Gag p24 in patients infected with different HIV-1 subtypes and correlation with HLA class I and II alleles.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
16. VERSTREPEN BE , Bins AD, Rollier CS, Mooij P, et al
    Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
17. ROSATI M , Valentin A, Jalah R, Patel V, et al
    Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
18. LI W , Li S, Hu Y, Tang B, et al
    Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
19. BRAVE A , Hallengard D, Schroder U, Blomberg P, et al
    Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
20. PALMA P , Romiti ML, Cancrini C, Pensieroso S, et al
    Delayed early antiretroviral treatment is associated with an HIV-specific long-term cellular response in HIV-1 vertically infected infants.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
21. STARODUBOVA ES , Boberg A, Litvina M, Morozov A, et al
    HIV-1 reverse transcriptase artificially targeted for proteasomal degradation induces a mixed Th1/Th2-type immune response.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
22. CALAROTA SA , Dai A, Trocio JN, Weiner DB, et al
    IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
23. GUDMUNDSDOTTER L , Bostrom AC, Burton C, Rosignoli G, et al
    Long-term increase of CD4(+) central memory cells in HIV-1-infected individuals by therapeutic HIV-1 rgp160 immunization.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
24. STEERS NJ , Alving CR, Rao M
    Modulation of immunoproteasome subunits by liposomal lipid A.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
25. SIMON AJ , Casimiro DR, Finnefrock AC, Davies ME, et al
    Enhanced in vivo transgene expression and immunogenicity from plasmid vectors following electrostimulation in rodents and primates.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
26. GRAY K , Legg K, Sharp A, Mackie N, et al
    Participation in two phase II prophylactic HIV vaccine trials in the UK.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
27. VALOR L , Navarro J, Carbone J, Rodriguez-Sainz C, et al
    Immunization with an HIV-1 immunogen induces CD4(+) and CD8(+) HIV-1-specific polyfunctional responses in patients with chronic HIV-1 infection receiving antiretroviral therapy.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    March 2008
28. JAOKO W , Nakwagala FN, Anzala O, Manyonyi GO, et al
    Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
29. NEWMAN PA , Duan N, Kakinami L, Roberts K, et al
    What can HIV vaccine trials teach us about future HIV vaccine dissemination?
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
30. LECOQ A , Moine G, Bellanger L, Drevet P, et al
    Increasing the humoral immunogenic properties of the HIV-1 Tat protein using a ligand-stabilizing strategy.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
31. HIRAO LA , Wu L, Khan AS, Hokey DA, et al
    Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    February 2008
32. YANG OO
    Retracing our STEP towards a successful CTL-based HIV-1 vaccine.
    Vaccine. 2008;.
    PubMed     Related articles   
    
    
    
33. HUANG Y , Chen A, Li X, Chen Z, et al
    Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
34. RASKA M , Moldoveanu Z, Novak J, Hel Z, et al
    Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
35. SINGH P , Kaur G, Sharma G, Mehra NK, et al
    Immunogenetic basis of HIV-1 infection, transmission and disease progression.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
36. HUTCHESON HB , Lautenberger JA, Nelson GW, Pontius JU, et al
    Detecting AIDS restriction genes: From candidate genes to genome-wide association discovery.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    January 2008
37. MIYAZAWA M , Tsuji-Kawahara S, Kanari Y
    Host genetic factors that control immune responses to retrovirus infections.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
38. CAPUTO A , Brocca-Cofano E, Castaldello A, Voltan R, et al
    Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
39. VANDEPAPELIERE P , Horsmans Y, Moris P, Van Mechelen M, et al
    Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
40. VANGELISTA L , Secchi M, Lusso P
    Rational design of novel HIV-1 entry inhibitors by RANTES engineering.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
41. WANG S , Kennedy JS, West K, Montefiori DC, et al
    Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    
42. JACOBS A , Garg H, Viard M, Raviv Y, et al
    HIV-1 envelope glycoprotein-mediated fusion and pathogenesis: Implications for therapy and vaccine development.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
43. BECK Z , Prohaszka Z, Fust G
    Traitors of the immune system-Enhancing antibodies in HIV infection: Their possible implication in HIV vaccine development.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
44. FERNANDES SJ , Slhessarenko N, Souto FJ
    Effects of vertical HIV infection on the persistence of anti-HBs after a schedule of three doses of recombinant hepatitis B vaccine.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
45. BORKOWSKY W , Yogev R, Muresan P, McFarland E, et al
    Structured treatment interruptions (STIs) in HIV-1 infected pediatric populations increases interferon gamma production and reduces viremia.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
46. NEWMAN PA , Daley A, Halpenny R, Loutfy M, et al
    Community heroes or "high-risk" pariahs? Reasons for declining to enroll in an HIV vaccine trial.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available
    
    
    December 2007
47. YIN L , Zhang Y, Qian HZ, Rui B, et al
    Willingness of Chinese injection drug users to participate in HIV vaccine trials.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
48. STOIBER H , Banki Z, Wilflingseder D, Dierich MP, et al
    Complement-HIV interactions during all steps of viral pathogenesis.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
49. RIVERA DS , McMurry JA, Buus S, Martin W, et al
    Identification of immunogenic HLA-B7 "Achilles' heel" epitopes within highly conserved regions of HIV.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
50. ALVING CR , Rao M
    Lipid A and liposomes containing lipid A as antigens and adjuvants.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
51. KOTWAL GJ
    Genetic diversity-independent neutralization of pandemic viruses (e.g. HIV), potentially pandemic (e.g. H5N1 strain of influenza) and carcinogenic (e.g. HBV and HCV) viruses and possible agents of bioterrorism (variola) by enveloped virus neutralizing co
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
52. SRIVASTAVA I , Goodsell A, Zhou F, Sun Y, et al
    Dynamics of acute and memory mucosal and systemic immune responses against HIV-1 envelope following immunizations through single or combinations of mucosal and systemic routes.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
53. PIACENTINI L , Fenizia C, Naddeo V, Clerici M, et al
    Not just sheer luck! Immune correlates of protection against HIV-1 infection.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
54. VELJKOVIC V , Veljkovic N, Glisic S, Ho MW, et al
    AIDS vaccine: Efficacy, safety and ethics.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
55. CAGIGI A , Nilsson A, De Milito A, Chiodi F, et al
    B cell immunopathology during HIV-1 infection: Lessons to learn for HIV-1 vaccine design.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
56. LEHNER T , Wang Y, Pido-Lopez J, Whittall T, et al
    The emerging role of innate immunity in protection against HIV-1 infection.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
57. BAYER W , Schimmer S, Hoffmann D, Dittmer U, et al
    Evaluation of the Friend Virus model for the development of improved adenovirus-vectored anti-retroviral vaccination strategies.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
58. GAVIOLI R , Cellini S, Castaldello A, Voltan R, et al
    The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
59. MARTINON F , Brochard P, Ripaux M, Delache B, et al
    Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
60. WYATT LS , Earl PL, Vogt J, Eller LA, et al
    Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    November 2007
61. LU L , Zhu Y, Diao J, Wang Z, et al
    V3 CTL epitope density in a single recombinant molecule antigen differentially affects the number and activity of primary and memory CD8(+) T cells.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
62. PIALOUX G , Hocini H, Perusat S, Silberman B, et al
    Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: The ANRS VAC14 study.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
63. GORSE GJ , Baden LR, Wecker M, Newman MJ, et al
    Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
64. HIRAO LA , Wu L, Khan AS, Satishchandran A, et al
    Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
65. MERCIER GT , Nehete PN, Passeri MF, Nehete BN, et al
    Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules.
    Vaccine. 2007;25:8689-8703.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    October 2007
66. SAINI M , Hadas E, Volsky DJ, Potash MJ, et al
    Vaccine-induced protection from infection of mice by chimeric human immunodeficiency virus type 1, EcoHIV/NL4-3.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
67. CAMPBELL GR , Senkaali D, Watkins J, Esquieu D, et al
    Tat mutations in an African cohort that do not prevent transactivation but change its immunogenic properties.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
68. GRECO R , Michel M, Guetard D, Cervantes-Gonzalez M, et al
    Production of recombinant HIV-1/HBV virus-like particles in Nicotiana tabacum and Arabidopsis thaliana plants for a bivalent plant-based vaccine.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
69. PUTHANAKIT T , Aurpibul L, Yoksan S, Sirisanthana T, et al
    Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
70. CHEN JM , Islam ST, Ren H, Liu J, et al
    Differential productions of lipid virulence factors among BCG vaccine strains and implications on BCG safety.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    September 2007
71. ZHOU Q , Hidajat R, Peng B, Venzon D, et al
    Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251).
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
72. HAMMONDS J , Chen X, Zhang X, Lee F, et al
    Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
73. HUANG X , Liu L, Ren L, Qiu C, et al
    Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
74. GUILLON C , Mayol K, Terrat C, Compagnon C, et al
    Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
75. ELLER MA , Eller LA, Opollo MS, Ouma BJ, et al
    Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
76. JOHNSON LF , Bekker LG, Dorrington RE
    HIV/AIDS vaccination in adolescents would be efficient and practical when vaccine supplies are limited.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
77. DONG XN , Chen Y, Chen YH
    Surface simulation synthesis: a new strategy to spy alpha-helix structure.
    Vaccine. 2007;25:6569-71.
    PubMed     Related articles    Abstract available
    
    
    August 2007
78. DUKE CM , Maguire CA, Keefer MC, Federoff HJ, et al
    HSV-1 amplicon vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
79. AIDOO M , Otten RA, Rodriguez V, Sariol CA, et al
    Absence of SHIV infection in gut and lymph node tissues in rhesus monkeys after repeated rectal challenges following HIV-1 DNA/MVA immunizations.
    Vaccine. 2007;25:6474-81.
    PubMed     Related articles    Abstract available
    
    
    
80. JIANG S , Rasmussen RA, Nolan KM, Frankel FR, et al
    Live attenuated Listeria monocytogenes expressing HIV Gag: Immunogenicity in rhesus monkeys.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
81. KITCHEN LW , Vaughn DW
    Role of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseases.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
82. BEYRER C , Baral S, Shaboltas A, Dukhovlinova E, et al
    The feasibility of HIV vaccine efficacy trials among Russian injection drug users.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    July 2007
83. BRAVE A , Hinkula J, Cafaro A, Eriksson LE, et al
    Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
84. PARKER SD , Rottinghaus ST, Zajac AJ, Yue L, et al
    HIV-1(89.6) Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in mice.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    
85. HESSELING AC , Cotton MF, Marais BJ, Gie RP, et al
    BCG and HIV reconsidered: Moving the research agenda forward.
    Vaccine. 2007;.
    PubMed     Related articles   
    
    
    June 2007
86. LOUTAN L , Bovier P, Herzog C
    Immunogenicity and safety of a virosomal hepatitis A vaccine in HIV-positive patients.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
87. MAYOL K , Munier S, Beck A, Verrier B, et al
    Design and characterization of an HIV-1 Tat mutant: Inactivation of viral and cellular functions but not antigenicity.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
88. PANCRE V , Delhem N, Yazdanpanah Y, Delanoye A, et al
    Presence of HIV-1 Nef specific CD4 T cell response is associated with non-progression in HIV-1 infection.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
89. BUONAGURO L , Devito C, Tornesello ML, Schroder U, et al
    DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
90. LAO-ARAYA M , Puthanakit T, Aurpibul L, Sirisanthana T, et al
    Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
91. BUCAY AH
    Clinical hypothesis: Application of AIDS vaccines together with thyroid hormones to increase their immunogenic effect.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    April 2007
92. TASTAN Y
    Comment on Hesseling, et al. "The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children" [Vaccine 25 (2006) 14-18].
    Vaccine. 2007;.
    PubMed     Related articles   
    
    
    March 2007
93. TARANTOLA D , Macklin R, Reed ZH, Kieny MP, et al
    Ethical considerations related to the provision of care and treatment in vaccine trials.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
94. CATANZARO AT , Roederer M, Koup RA, Bailer RT, et al
    Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
95. KARPENKO LI , Ilyichev AA, Eroshkin AM, Lebedev LR, et al
    Combined virus-like particle-based polyepitope DNA/protein HIV-1 vaccine Design, immunogenicity and toxicity studies.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    February 2007
96. XIN KQ , Sekimoto Y, Takahashi T, Mizuguchi H, et al
    Chimeric adenovirus 5/35 vector containing the clade C HIV gag gene induces a cross-reactive immune response against HIV.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    

Thank you for your interest in scientific medicine.

This AMEDEO Service was made possible thanks to the generous unrestricted educational grants provided by Boehringer Ingelheim and Pfizer.

Amedeo is a Bernd Sebastian Kamps website.    Design: